Search

This work presents recombination methods used for secondary radiation measurements at the Facility for Proton Radiotherapy of Eye Cancer at the Institute for Nuclear Physics, IFJ, in Krakow (Poland). The measurements of H*(10) were performed, with REM-2 tissue equivalent chamber in two halls of cyclotrons AIC-144 and Proteus C-235 and in the corridors close to treatment rooms. The measurements were completed by determination of gamma radiation component, using a hydrogen-free recombination chamber. The results were compared with the measurements using rem meter types FHT 762 (WENDI-II) and NM2 FHT 192 gamma probe and with stationary dosimetric system.

The radiation environment encountered in space differs in nature from that on Earth, consisting mostly of highly energetic ions from protons up to iron, resulting in radiation levels far exceeding the ones present on Earth for occupational radiation workers. Since the beginning of the space era, the radiation exposure during space missions has been monitored with various active and passive radiation instruments. Also onboard the International Space Station (ISS), a number of area monitoring devices provide data related to the spatial and temporal variation of the radiation field in and outside the ISS. The aim of the DOSIS (2009–2011) and the DOSIS 3D (2012–ongoing) experiments was and is to measure the radiation environment within the European Columbus Laboratory of the ISS. These measurements are, on the one hand, performed with passive radiation detectors mounted at 11 locations within Columbus for the determination of the spatial distribution of the radiation field parameters and, on the other, with two active radiation detectors mounted at a fixed position inside Columbus for the determination of the temporal variation of the radiation field parameters. Data measured with passive radiation detectors showed that the absorbed dose values inside the Columbus Laboratory follow a pattern, based on the local shielding configuration of the radiation detectors, with minimum dose values observed in the year 2010 of 195–270 μGy/day and maximum values observed in the year 2012 with values ranging from 260 to 360 μGy/day. The absorbed dose is modulated by (a) the variation in solar activity and (b) the changes in ISS altitude.

A direct verification of the three-dimensional (3D) proton clinical treatment plan prepared for tumor in the eyeball, using the Eclipse Ocular Proton Planning system (by Varian Medical Systems), has been presented. To achieve this, a prototype of the innovative two-dimensional (2D) circular silicone foils, made of a polymer with the embedded optically stimulated luminescence (OSL) material in powder form (LiMgPO4), and a self-developed optical imaging system, consisting of an illuminating light source and a high-sensitive CCD camera has been applied. A specially designed lifelike eyeball phantom has been used, constructed from 40 flat sheet LMP-based silicone foils stacked and placed together behind a spherical phantom made by polystyrene, all to reflect the curvature of the real eyeball. Two-dimensional OSL signals were captured and further analyzed from each single silicone foil after irradiation using a dedicated patient collimator and a 58.8 MeV modulated proton beam. The reconstructed 3D proton depth dose distribution matches very well with the clinical treatment plan, allowing for the consideration of the new OSL system for further 3D dosimetry applications within the proton radiotherapy area. [ABSTRACT FROM AUTHOR]

Objective. Determining and verifying the number of monitor units is crucial to achieving the desired dose distribution in radiotherapy and maintaining treatment efficacy. However, current commercial treatment planning system(s) dedicated to ocular passive eyelines in proton therapy do not provide the number of monitor units for patient-specific plan delivery. Performing specific pre-treatment field measurements, which is time and resource consuming, is usually gold-standard practice. This proof-of-concept study reports on the development of a multi-institutional-based generalized model for monitor units determination in proton therapy for eye melanoma treatments. Approach. To cope with the small number of patients being treated in proton centers, three European institutes participated in this study. Measurements data were collected to address output factor differences across the institutes, especially as function of field size, spread-out Bragg peak modulation width, residual range, and air gap. A generic model for monitor units prediction using a large number of 3748 patients and broad diversity in tumor patterns, was evaluated using six popular machine learning algorithms: (i) decision tree; (ii) random forest, (iii) extra trees, (iv) K-nearest neighbors, (v) gradient boosting, and (vi) the support vector regression. Features used as inputs into each machine learning pipeline were: Spread-out Bragg peak width, range, air gap, fraction and calibration doses. Performance measure was scored using the mean absolute error, which was the difference between predicted and real monitor units, as collected from institutional gold-standard methods. Main results. Predictions across algorithms were accurate within 3% uncertainty for up to 85.2% of the plans and within 10% uncertainty for up to 98.6% of the plans with the extra trees algorithm. Significance. A proof-of-concept of using machine learning-based generic monitor units determination in ocular proton therapy has been demonstrated. This could trigger the development of an independent monitor units calculation tool for clinical use., (Creative Commons Attribution license.)